NCT06300216 A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors Status NOT_YET_RECRUITING Phase N/A
NCT06263088 EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. Status RECRUITING Phase NA
NCT06232564 A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06204159 Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery Status ACTIVE_NOT_RECRUITING Phase NA
NCT06159920 Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors. Status RECRUITING Phase N/A
NCT06155994 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours Status COMPLETED Phase PHASE1/PHASE2
NCT06148636 A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors Status ACTIVE_NOT_RECRUITING Phase EARLY_PHASE1
NCT06143605 Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors Status COMPLETED Phase N/A
NCT06122610 Using Novel Imaging to More Safely Treat Neuroendocrine Tumors Status COMPLETED Phase PHASE1
NCT06121752 Device Assisted Full Thickness Resection Versus Endoscopic Submucosal Dissection for Duodenal Neuroendocrine Tumors Status RECRUITING Phase NA
NCT06056362 Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors Status RECRUITING Phase PHASE1/PHASE2
NCT06055439 A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy Status RECRUITING Phase PHASE1/PHASE2
NCT06041516 A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors Status RECRUITING Phase PHASE1
NCT06038461 An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors Status RECRUITING Phase PHASE1/PHASE2
NCT06015802 Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors Status RECRUITING Phase N/A
NCT05997056 Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors Status RECRUITING Phase PHASE2
NCT05987176 Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases Status TERMINATED Phase PHASE2